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Schizophrenia affects around one in every 100
people during their lifetime. First symptoms are
typically experienced between the ages of 15 and
35, and the disease affects men and women
equally. Incidence is higher in cities, and in
migrant and ethnic minority groups.2
Schizophrenia is a psychiatric disorder that
alters an individual’s perception, thoughts, affect
and behaviour.3 It can often be distressing for
individuals and their family, and can influence 
their personal, social and occupational lives. Early
and accurate diagnosis, intervention and the
selection of effective treatment(s) are paramount
in improving quality of life.
Symptoms
The symptoms of schizophrenia are typically
categorised into positive and negative types. 
Hallucinations (including auditory and visual),
delusional beliefs, behavioural problems and
thought disorder form the positive symptoms and
would be most prominent during the acute phase
of the illness. These are often referred to as the
psychotic symptoms of schizophrenia.
Negative symptoms include lack of 
motivation, energy and emotions, distortions 
of thought and speech, and social withdrawal.
These symptoms are typical of the chronic phase
of schizophrenia. They can be difficult to treat with
medicines, but can be helped by psychological
interventions. 
The European criteria for diagnosing
schizophrenia are outlined by the World Health
Organization in the International Classification of
Diseases, 10th edition.4
What causes schizophrenia?
The causes of schizophrenia are not fully
understood. It is thought that individuals possess
different levels of vulnerability determined by a
combination of genetic, psychological, social,
environmental and biochemical factors.3
Biochemical theories include the disruption of
various neurotransmitter pathways such as
glutamate, serotonin and gamma-aminobutyric
acid (GABA). However, most research and
treatments focus on blockade of the overactive D2
dopamine receptors in the brain’s pre-frontal
cortex, in particular the mesolimbic area. Elevated
dopamine levels can interrupt important cognitive,
motor and emotional functions, leading to the
psychotic symptoms of schizophrenia.
Drug treatment
Since their introduction in the 1950s,
antipsychotics remain the mainstay of treatment.
They predominantly (or partially with respect to
aripiprazole) block D2 dopamine receptors in the
mesolimbic area of the brain, thereby lowering
dopamine concentrations. 
There is little difference in efficacy between the
available antipsychotics, apart from clozapine,
which is licensed for treatment-resistant
schizophrenia, but they are categorised into
‘typical’ and ‘atypical’ based primarily on their
pharmacology and side effect profiles.
Typical antipsychotics (‘first generation’) act
with similar efficiency by predominantly blocking
D2 dopamine receptors. However, they differ in
their ability to block other receptors, such as
histamine and cholinergic receptors, thus
producing diverse adverse effect profiles. 
Typical antipsychotics are usually associated 
with increased extrapyramidal side effects 
(EPSE) and sedation.
Atypical or second generation antipsychotics
block dopamine receptors more selectively 
than typical antipsychotics, decreasing the
likelihood of EPSE. Furthermore, their novel
pharmacology in blocking serotonin 2a receptors
was initially thought to contribute to the atypical
antipsychotics’ greater efficacy on the negative
symptoms of schizophrenia and their more
tolerable side effect profiles. However, recent
studies suggest that this binding is unrelated to the
efficacy or adverse effect profile, and again raise
uncertainty about their exact mode of action.3
Adverse effects
The adverse effects of antipsychotics can be
predicted according to the individual drug’s
pharmacology. Dopamine blockade in areas of 
the brain other than the mesolimbic area can 
give rise to adverse effects. Dopamine blockade 
in the nigrostriatal pathway is thought to produce
EPSE. Similarly, dopamine blockade in the
tuberoinfundibular pathway causes raised
prolactin levels (leading to sexual dysfunction and
menstrual irregularities) and dopamine blockade
in the mesocortical pathway gives rise to
cognitive side effects.
EPSE can be particularly troublesome and
include parkinsonian symptoms (including
tremor), akathisia (restlessness), dystonia
(abnormal face and body movements) and
dyskinesia, and tardive dyskinesia (rhythmic,
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involuntary movements of tongue, face and jaw).
These adverse effects significantly contribute to
the reduced quality of life suffered by patients.
Antipsychotics’ effect on different receptors also
cause other side effects such as dry mouth, blurred
vision, constipation, urinary retention (cholinergic
blockade), sedation (histamine blockade), postural
hypotension, dizziness and syncope (alpha
antagonism). 
Table 1 (in the full version of this article online at
www.chemistanddruggist.co.uk/update) describes
the adverse effects of commonly used
antipsychotics and exhibits their heterogeneity.
Choice of antipsychotics
Until recently, Nice had recommended atypical
antipsychotics as the first-line treatment in people
with newly diagnosed schizophrenia and for
patients already prescribed typical antipsychotics
for whom treatment response was inadequate or
who suffered adverse effects.7 However, in March
2009 the advice was rephrased to state that the
choice of antipsychotic drug should:
• be made in discussion with the patient• take into account the views of the carer• reflect the degree of sedation required 
The relative potential of individual
antipsychotic drugs to cause EPSE, metabolic side
effects (including weight gain and cardiovascular
problems) and other adverse effects such as
unpleasant subjective experiences should also be
taken into consideration.3,8
This was in direct response to emerging evidence
that atypical antipsychotics do not possess greater
efficacy or tolerability than typical antipsychotics.
Although atypical antipsychotics have a lower
propensity to induce EPSE, they nevertheless have
an adverse effect profile of their own that can
significantly affect the individual’s morbidity and
mortality.3, 9, 10
Table 2 (in the full version of this article online at
www.chemistanddruggist.co.uk/update) outlines
choice of antipsychotics when certain side effects
are particularly troublesome.
Treatment resistant
schizophrenia
Clozapine is a unique atypical antipsychotic in
that it is recognised as being particularly effective
when conventional agents have failed. It is
documented to reduce the risk of suicide in
schizophrenia and is especially useful for quelling
violence and aggression in difficult cases.11
Clozapine’s mode of action involves antagonism
of dopamine and serotonin receptors, but it is
unclear why the drug has a higher level of efficacy.
In contrast, it can produce life-threatening and
potentially fatal agranulocytosis, a condition
involving a dangerous fall in white blood cells. 
Regular (initially weekly) blood tests and
registration for healthcare professionals and
patients with the clozapine monitoring service are
mandatory before supply can be made. Clozapine
can also increase the risk of seizures, cause weight
gain, diabetic keto-acidosis and possibly has the
greatest cardiometabolic risk among the
antipsychotics.
Nice guidance states that clozapine should be
offered to people with schizophrenia whose illness
has not responded adequately to treatment
despite the sequential use of adequate doses of at
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least two different antipsychotic drugs, one of
them being a non-clozapine second-generation
antipsychotic.3 However, in practice the initiation
of treatment with clozapine is often delayed
unnecessarily, probably because of its impractical
monitoring regimes (for needle-phobic or patients
in whom oral adherence cannot be assured) and
the fear of side effects.
Formulations
Antipsychotics can be administered orally or by
long-acting depot injections. Where oral
administration is not suitable, for example for
those patients who cannot reliably remember to
take their treatment, a long-acting intramuscular
‘depot’ formulation that can be injected at weekly,
fortnightly or monthly intervals may be desirable.
In addition to liquid preparations, oral
dispersible formulations that dissolve on the
tongue or disperse in drinks are also available. They
can be taken under supervision, so are particularly
useful if the patient is non-adherent with the
medication. 
Points to note
There is no benefit in prescribing more than one
antipsychotic at the same time and could cause
significant harm.
Particular care should be taken when treating
patients with dementia, pre-existing or history of
cardiovascular disease, stroke, epilepsy, diabetes
and Parkinson’s disease, and the elderly.
Treatment packages should include regular
electrocardiogram (ECG) and biochemical testing
(liver function test abnormalities, electrolyte
imbalances, full blood counts, plasma glucose,
prolactin and lipid levels), together with a review of
the patient’s physical health status (eg weight,
blood pressure) and drug adverse effects.
Following baseline assessments at the initiation of
treatment, these tests should be repeated every six
to 12 months.3
Non-pharmacological
treatment
Psychological and psychosocial interventions can
be used to reduce symptoms, increase insight,
prevent relapse and to promote adherence.
Cognitive behavioural therapy (CBT), family
interventions and art therapy are particularly
highlighted by Nice.3 CBT attempts to allow
individuals to manage their thoughts and
behaviour in order to control their symptoms, 
and should be offered to all patients with
schizophrenia. 
Family interventions provide education and
support for those who are close to the patient,
allowing them to manage problems effectively. In
addition, art therapy aims to promote creative
expression and is particularly effective for
managing or reducing negative symptoms. These
interventions are especially useful when medicines
do not fully relieve symptoms.
Counselling
It is important for patients to realise that
schizophrenia can be a lifelong condition.
Adherence to treatment packages is of the
upmost importance and pharmacists must
provide support to ensure treatment meets the
patient’s needs. Treatment interventions have to
be effective and without unwanted side effects. 
Patients should be encouraged to discuss their
illness and treatment beliefs to improve
adherence. Counselling on weight management,
alcohol use, driving, smoking, complementary
treatments and over the counter medications is
useful. 
Patients should be educated on how their
medication works, administration regimes, drug
interactions and side effects to improve adherence.
In particular, patients should be told to report
unexplained symptoms, especially fever, muscle
rigidity, fluctuating consciousness and sweating
that resemble the rare, but potentially fatal side
effect of antipsychotics known as neuroleptic
malignant syndrome. Support should be given to
the family, and information on non-drug
treatments and support groups is valuable.
Summary
The management of schizophrenia involves 
a comprehensive care package that often includes
pharmacological treatment. Treatment adherence
is of great importance and patients must be
educated to ensure they engage in their
treatment. For this long-term treatment to be
successful clinicians must also engage with the
treatment and illness beliefs of patients and 
their carers.
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Further Information
1. Mind. Online at www.mind.org.uk. A UK mental
health charity that focuses on various psychiatric
illnesses.
2. Rethink. Online at www.rethink.org. Also a
national charity focusing on mental illnesses and
provides information on support groups.
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Locum pharmacist Salma Hussain is
working in a pharmacy in a deprived
area. She is at the prescription
reception area one morning when a
woman comes in with two
prescriptions. The woman signs the
declaration on the reverse of the
first one that she is receiving income
support and claiming exemption.
Salma asks her if she has anything to
show that she is receiving the
benefit. The woman looks irritated
and says: “No, not on me. And
anyway, they’ve never asked me for
anything here before.”
Salma takes the script and ticks
Practical Approach Test yourself in this everyday pharmacy scenario
the ‘evidence not seen’ box. The
woman starts to sign the exemption
declaration on the second
prescription. She asks Salma which
box she should tick.
“Who is it for?” Salma asks.
“My son.”
“How old is he?”
“Eighteen.”
“Is he at school or college?”
“No, he’s got a full-time job.”
“Well,” says Salma, “I’m afraid that
you’re going to have to pay the
prescription charge. There are three
items here, so it’s £21.60.”
“What!” retorts the woman. “We
can’t afford to pay that! I’m just
going to tick that he’s on jobseeker’s
allowance.”   
Before Salma can say anything
more the senior sales assistant, 
who has been listening to the
conversation, intervenes and says to
Salma: “This is a very poor area. The
owner says that we can’t deprive 
our customers of medicines they
need if they can’t afford to pay the
prescription charge. He says that it’s
not our responsibility to check if their
exemption declarations are correct.
We just tick the ‘evidence not seen’
box and dispense the script.”  
However, the RPSGB states:
“Pharmacists are reminded to check
that the declaration on the back of
the prescription form has been filled
in correctly... where a patient (or his
or her representative) declares an
exemption from prescription charges,
the pharmacist is required to check
for evidence of this… a false
declaration made by the pharmacist,
whether knowingly or as a result of
failure to check a patient’s
exemption, may constitute a criminal
offence or professional misconduct
or both.” (www.rpsgb.org.uk/pdfs/
LEBpreventNHSfraud.pdf)
2. This question is best answered by
those practising at the frontline –
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Questions
1. Do pharmacy staff have a
responsibility to verify that a
patient’s declaration of exemption
is genuine?
2. Is it morally right to turn a
blind eye to a false declaration of
exemption entitlement if a
patient genuinely cannot afford
to pay? 
Answers
1. PSNC’s views (for England) and
the RPSGB’s appear to conflict.
PSNC states: “Where patients do
not have evidence or where there is
doubt over whether the evidence
provided is genuine or appropriate,
the ‘evidence not seen' box on the
back of the prescription should be
marked with an X by pharmacy staff.
Pharmacy staff should not refuse to
dispense items on the basis that the
patient does not provide evidence of
their entitlement to free
prescriptions. Pharmacy contractors
are in no way responsible for the
accuracy of a patient’s declaration;
this remains the responsibility of 
the patient.” (www.psnc.org.uk/
pages/points_of_dispensing_checks_
guidance.html)
What are the positive symptoms of schizophrenia? How
do typical antipsychotics work? What are the side effects
of atypical antipsychotics? What problems are
associated with clozapine?
This article describes the symptoms, causes and
treatment of schizophrenia. It includes information
about typical and atypical antipsychotics, and their
adverse effects. It also discusses treatment with
clozapine and non-drug treatments.
• Find out more about the symptoms, causes 
and treatment of schizophrenia from the Royal 
College of Psychiatrists’ website at
http://tinyurl.com/schizophrenia-1.
• Read more about cognitive behavioural therapy 
and how it can help patients with schizophrenia on 
the Royal College of Psychiatrists’ website at
http://tinyurl.com/bm4x7m.
• Revise your knowledge of the different drugs and
formulations available by reading the BNF section 4.2.1
on antipsychotic drugs.
• Find out more about neuroleptic malignant 
syndrome from the Patient UK website at
http://tinyurl.com/murs9b. 
Are you now confident in your knowledge of the
symptoms and causes of schizophrenia? Are you familiar
with the drugs used in its treatment and their side
effects? Could you give advice to patients and carers
about schizophrenia?
Reflect
Act
Evaluate
Plan
Do you have an idea for a Practical
Approach scenario or would you
like to write one? Email us at:  
haveyoursay@
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Drug EPSE Weight Prolactin Anti Postural Sedation Cardiac
gain elevation cholinergic hypotension  
Chlorpromazine (o)
Flupentixol (o/d)
Fluphenazine (d)
Haloperidol (o/i/d)
Pipotiazine (d)
Sulpiride (o)
Trifluoperazine (o)
Zuclopentixol (o/d)
Amisulpride (o)
Aripiprazole (o/i)
Clozapine (o)
Olanzapine (o/i)
Quetiapine (o)
Risperidone (o/d)
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Side effects
+++ marked effect  ++ moderate effect  + mild/transient effect   – little or minimal effect
? No information or little reported
Formulations available:
o = oral  i = short-acting injection  d = long-acting intramuscular depot injection
Table 1: The incidence of adverse effects of 
some antipsychotics and available formulations
(Adapted from Psychotropic Drug Directory 2010, Stephen Bazire, and The Maudsley Guidelines 10th Edition 2009)5,6
Typical antipsychotics
Atypical antipsychotics
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Table 2. Choice of antipsychotics to manage certain adverse effects
(Adapted from The Maudsley Prescribing Guideleines 10th Edition 2009)6
Adverse effect Suggested drug Alternatives
Acute EPSE
Hyperprolactinaemia
(raised prolactin)
Weight gain
Tardive dyskinesia
Impaired glucose tolerance
QT prolongation
Sedation
Postural hypotension
Aripiprazole, quetiapine,
olanzapine
Aripiprazole,* quetiapine
Amisulpride, haloperidol,
trifluoperazine, aripiprazole*
Clozapine
Amisulpride, aripiprazole*
Aripiprazole (with ECG
monitoring)
Amisulpride, aripiprazole,
risperidone, sulpiride
Amisulpride, aripiprazole,
Sulpiride, haloperidol,
trifluoperazine
Clozapine, risperidone (less
than 6mg/day)
Clozapine, olanzapine
Quetiapine, risperidone
Olanzapine, quetiapine,
aripiprazole
Risperidone
Any low dose monotherapy
with ECG monitoring
Haloperidol, trifluoperazine
* There is evidence that both switching to and co-prescription of aripiprazole is effective in reducing weight,
prolactin and in reversing impaired glucose tolerance.
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